Sunil Goenka1, Satyaranjan Sethi2, Nitin Pandey1, Mrinal Joshi1, Rajeswari Jindal1. 1. Department of Physical Medicine and Rehabilitation, Sawai Man Singh Medical College, Jaipur, 302004, Rajasthan, India. 2. Department of Physical Medicine and Rehabilitation, Sawai Man Singh Medical College, Jaipur, 302004, Rajasthan, India. drsatya.1979@gmail.com.
Abstract
STUDY DESIGN: Randomized controlled trial. OBJECTIVES: To determine the effect of zoledronic acid on bone loss in people with acute spinal cord injury (SCI) SETTINGS: Sawai Man Singh Medical College, India. METHODS:Sixty patients with acute SCI were randomized to receive either standard treatment alone or standard treatment with zoledronic acid within 3 months after injury. Areal bone mineral density (aBMD) was measured at the hip using dual-energy X-ray absorptiometry (DXA) at baseline 3, 6, and 12 months. RESULTS: Significant differences in aBMD were found between the standard treatment alone and standard treatment plus zoledronic acid group at the femoral neck (-0.13; 95% CI, -0.18 to -0.09, p < 0.0001), and total hip (-0.16; 95% CI, -0.19 to -0.12, p < 0.0001), respectively, at 1 year and bone loss was reduced in the zoledronic acid treated group as compared to the standard treatment group. Significant differences in aBMD between the groups at 6 months post infusion was also observed at these sites. [Femoral neck -0.08; 95% CI, -0.12 to -0.03; p = 0.002 and total hip -0.12; 95% CI, -0.15 to -0.08; p < 0.0001] CONCLUSION: A zoledronic acid 5 mg infusion given within 3 month significantly reduces bone loss at the hip after 6 months post infusion in patients with acute SCI.
RCT Entities:
STUDY DESIGN: Randomized controlled trial. OBJECTIVES: To determine the effect of zoledronic acid on bone loss in people with acute spinal cord injury (SCI) SETTINGS: Sawai Man Singh Medical College, India. METHODS: Sixty patients with acute SCI were randomized to receive either standard treatment alone or standard treatment with zoledronic acid within 3 months after injury. Areal bone mineral density (aBMD) was measured at the hip using dual-energy X-ray absorptiometry (DXA) at baseline 3, 6, and 12 months. RESULTS: Significant differences in aBMD were found between the standard treatment alone and standard treatment plus zoledronic acid group at the femoral neck (-0.13; 95% CI, -0.18 to -0.09, p < 0.0001), and total hip (-0.16; 95% CI, -0.19 to -0.12, p < 0.0001), respectively, at 1 year and bone loss was reduced in the zoledronic acid treated group as compared to the standard treatment group. Significant differences in aBMD between the groups at 6 months post infusion was also observed at these sites. [Femoral neck -0.08; 95% CI, -0.12 to -0.03; p = 0.002 and total hip -0.12; 95% CI, -0.15 to -0.08; p < 0.0001] CONCLUSION: A zoledronic acid 5 mg infusion given within 3 month significantly reduces bone loss at the hip after 6 months post infusion in patients with acute SCI.
Authors: N L Gilchrist; C M Frampton; R H Acland; M G Nicholls; R L March; P Maguire; A Heard; P Reilly; K Marshall Journal: J Clin Endocrinol Metab Date: 2007-01-16 Impact factor: 5.958
Authors: Leo Widler; Knut A Jaeggi; Markus Glatt; Klaus Müller; Rolf Bachmann; Michael Bisping; Anne-Ruth Born; Reto Cortesi; Gabriela Guiglia; Heidi Jeker; Rémy Klein; Ueli Ramseier; Johann Schmid; Gerard Schreiber; Yves Seltenmeyer; Jonathan R Green Journal: J Med Chem Date: 2002-08-15 Impact factor: 7.446
Authors: Jill M Slade; C Scott Bickel; Christopher M Modlesky; Sharmila Majumdar; Gary A Dudley Journal: Osteoporos Int Date: 2004-08-28 Impact factor: 4.507
Authors: Frances M Weaver; Bella Etingen; Marylou Guihan; Cara Ray; Michael Priebe; Stephen Burns; Laura Carbone Journal: J Spinal Cord Med Date: 2019-12-20 Impact factor: 1.985
Authors: Gary J Farkas; Alicia Sneij; David W McMillan; Eduard Tiozzo; Mark S Nash; David R Gater Journal: Br J Nutr Date: 2021-09-23 Impact factor: 4.125